val-1221
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT02898753)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- val-1221
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02898753 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Valerion Therapeutics, LLC |
| NCT05930223 | N/A | — | Parasail, LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Parasail, LLC | For profit | 1 | 1 | 1 | — |
| Valerion Therapeutics, LLC | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1